

Patient with Severe Re-Occurring Hidradenitis Treated with Fentonite-Based Hydrogel That Resolved Ulcers and Fistulas in Five Weeks

Robert G Frykberg, DPM, MPH; Michael Labor, MD; Jessica Barcelo, CCMA

PATIENT BACKGROUND

EG is a 40-year-old patient with severe re-occurring hidradenitis. Hidradenitis suppurativa, especially in its severe form, causes significant discomfort and disability. As the disease progresses from mild to severe, the symptoms and pain intensify and become more widespread. EG has a difficulty with compliance due to multiple lifestyle items and work.

EG has a history of type two diabetes, hypertension, asthma and tobacco use. Historically, EG has had hidradenitis with ulcerations in the perirectal area and the axillary areas. She presented to Tucson Medical Center emergency room with a peri vulvar abscess and peri rectal fistula and abscess. The wounds were debrided by a TMC surgeon that further excised the necrotic tissue. The resulting wounds were a 6.5 x 4.5 vulvar wound and a 2.5 x 2.5 perirectal wound.


TREATMENT PLAN

EG was sent to our clinic for follow up care. Her first visit at the clinic was April 28, 2023. EG was in a lot of pain and discomfort. She was treated with TrueRelief (a neuromodulation device to improve blood flow and pain control). The patient's wounds were cleansed and then dressed with AgFresh®. The wounds were covered with 4X4 gauze. The patient was seen daily to assess the healing progress. The patient immediately got pain relief after the application of the AgFresh™ and TrueRelief treatment.


OUTCOME

EG responded well to the AgFresh® treatment plan and healed in 5 weeks. The patient was released from our care.


5/2/23 VULVAR ULCER




5/17/23 VULVAR ULCER



5/24/23 VULVAR ULCER



6/7/23 VULVAR ULCER



AgFresh® is a combination of two patented technologies, Fentonite® and BioBlock®, that provide a revolutionary approach to wound care. Both technologies are scientifically proven to dissolve biofilms and to inhibit the pathogen communication required to anchor and spread within the wound environment. Fentonite® is a blend of cationic minerals that have a cationic exchange capacity (CEC) that exceeds 250. The oxygen reactive potential of Fentonite® exceeds 400 and the pH is less than 3.5. This combination is unique to Fentonite® and provides the basis

for broad-based antimicrobial activity, based upon its antimicrobial characteristics and the communication requirements of biofilms. BioBlock® is a combination of 3 poloxamers that encapsulate Octenidine to improve its antimicrobial activity within biofilm structures. Each of the three poloxamers have a designated purpose and provide a holistic approach to biofilm and pathogen removal. The poloxamer micelles time release Octenidine into the biofilm and pathogens within the biofilm.

5/17/23 PERIRECTAL FISTULA



5/26/23 PERIRECTAL FISTULA



6/7/23 PERIRECTAL FISTULA



INVESTIGATORS

Michael Labor, MD is Medical Director of Saguaro Wound Care Clinic. He served as Dept. Chairman for General and Vascular Surgery at Tucson Medical Center, and Chief of Surgery and Staff at El Dorado Hospital. He is board certified in general surgery and fellow in the American College of Surgeons. He's past president of the Rocky Mountain Vascular Surgical Society, a Fellow in the Southwestern Surgical Congress. He was Commander/OIC of a surgical base in Afghanistan, 2012-2013.



Jessica Barcelo (CCMA) is a clinically certified medical assistant. She served two years as clinical lead for an urgent care center with an additional two-years experience as a wound care specialist.
7140 E. Rosewood Street, Suite 110 - Tucson, AZ 85710
Phone (520) 633-1715 • Saguarowoundcare@gmail.com